|
On the cutting edge
June 2015
EDIT CONNECT
SHARING OPTIONS:
We have a trio of stories this month, with Agilent forging deals with Cartagenia and Scion, QIAGEN
partnering with BGI and N-of-One announcing that CellNetix has adopted its technology.
Agilent to acquire
Cartagenia and forge agreement with Scion
SANTA CLARA, Calif.—On May 4, Agilent Technologies Inc. and Cartagenia
announced that they had signed a definitive agreement under which Agilent will acquire Cartagenia, a provider of software and services for variant assessment
and reporting of clinical genomics data from next-generation sequencing and microarrays that is based in Boston and Leuven, Belgium.
“Cartagenia’s approach to enabling the interpretation of clinical genomics data is revolutionary,” said
Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group. “We look forward to providing Cartagenia’s software solutions to our
clinical genetics and molecular oncology customers and to providing Cartagenia’s existing customers with access to our global service and support
network. Together, Agilent and Cartagenia can help remove bottlenecks inherent in analysis, interpretation and reporting clinical data, resulting in faster
answers for patients.”
Cartagenia employs 36 people, all of whom will be offered employment with Agilent.
Financial terms of the transaction were not disclosed.
In late April, Agilent and Scion Instruments announced a gas chromatography (GC) instrument control agreement that will
provide customers the freedom to operate instruments from both manufacturers in each company’s chromatography data systems. The companies will exchange
development documentation and royalty-free licenses of driver software for the integration of each other’s GC instruments into their respective
chromatography data systems. With the development of these drivers, GC systems from either manufacturer will be integrated into Agilent’s OpenLAB CDS
EZChrom Edition and Scion’s CompassCDS chromatography data systems.
With Agilent’s Instrument Control
Framework and Rapid Control driver technology, Scion’s 3000- and 400-series gas chromatographs—including the latest SCION 436 and 456
models—can be used with Agilent’s OpenLAB CDS software. Likewise, Scion’s CompassCDS will support Agilent’s 6890 and 7890 Series gas
chromatographs.
“We are continuously expanding OpenLAB CDS multivendor instrument control capabilities in
collaboration with other analytical instrument manufacturers and are working to standardize analytical instrument control across data systems, resulting in
the best-working and best-tested software for our mutual customers,” said John Sadler, Agilent vice president and general manager of software and
informatics
QIAGEN partners with world’s largest sequencing provider
REDWOOD CITY, Calif.—QIAGEN N.V. announced in May that it had
expanded its relationship with China-based BGI, said to be the world’s largest genomics
organization, to provide QIAGEN’s Ingenuity Variant Analysis in integrated bioinformatics for all customers of BGI’s sequencing services.
Under the reseller agreement, BGI customers will receive sequencing data generated from their samples through Ingenuity
Variant Analysis’ secure, cloud-based environment and gain access to its leading comprehensive gene variant data and genomic interpretation
applications. BGI will provide Ingenuity Variant Analysis to customers in China, Hong Kong and Taiwan, with plans to expand to other regions throughout the
year.
“Bioinformatics solutions from QIAGEN are growing rapidly as scientists and healthcare professionals
increasingly use genomic information to guide research and provide precise diagnosis for medical decision-making,” said Laura Furmanski, head of
QIAGEN’s Bioinformatics Business Area. “We are committed to working with leading organizations such as BGI to make these improvements in life
possible.”
“Coupling BGI’s world-class sequencing with the deep bioinformatics of Ingenuity
Variant Analysis will give researchers an enhanced, integrated way to seamlessly move quickly from raw data to valuable insights,” added Yingrui Li,
chief scientist of BGI.
CellNetix Adopts N-of-One TrialMatch
LEXINGTON, Mass.—In mid-May, N-of-One Inc., a provider of clinical interpretation
evidence, announced that CellNetix Pathology and Laboratories had adopted N-of-One’s new
clinical trial matching solution, TrialMatch, as well as N-of-One clinical interpretation evidence services. Under this agreement, N-of-One will provide
industry-leading clinical interpretation evidence as well as molecular profile-based clinical trial matching for CellNetix next-generation sequencing cancer
genomics tests. Financial terms of the agreement were not disclosed.
“Clinical trial matching is central to
enabling clinicians to identify the best therapeutic options for their cancer patients,” said Dr. Anna Berry, medical director of molecular diagnostics
at CellNetix and scientific director of the Personalized Medicine Program at the Swedish Cancer Institute. “CellNetix has adopted N-of-One TrialMatch
and clinical interpretation evidence services because together they provide the most comprehensive, patient-specific molecular profile to inform high-quality
clinician decision-making.”
“The key to the success of TrialMatch is N-of-One clinical interpretation
evidence,” said Jennifer Levin Carter, chief medical officer of N-of-One. “Successful clinical trial matching requires patient-specific molecular
profiling at the gene-variant-disease level based on comprehensive, up-to-date scientific and clinical evidence, which is a fundamental capability of N-of-
One.”
Code: E061527 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|